Research Article | Volume: 3, Issue: 2, February, 2013

Molecular docking studies of guggultetrol from Nymphaea pubescens with target glucokinase (GK) related to type-II Diabetes

Kiran Kumar Angadi Ravi Kumar Gundampati Medicherla V. Jagannadham Ammani Kandru   

Open Access   

Published:  Feb 27, 2013

DOI: 10.7324/JAPS.2013.30222

Diabetes prevalence is one of the life threatening diseases in India. In this work we address a specific suitable ligand for diabetes mellitus. A large focus has been on structure based drug designing. Guggultetrol isolated from Nymphaea pubescens was taken as ligand for molecular docking. A theoretical docking study, the evaluation of guggultetrol as inhibitor of Glucokinase (PDB ID: 1V4S) a validated drug target enzyme of the Type-II diabetes, was taken up. Guggultetrol was found to bind at active site of glucokinase with lowest binding energy and RMSD values to be -9.45Kcal/Mol and 2.0 Å respectively. Docking analysis of 1V4S with ligand enabled us to identify specific residues viz. Thr-168, Glu-290, Glu-51, Ser-411, Gly-410, Asn-254, Thr-206, Arg-155 and Asp-205 within the 1V4S binding pocket to play an important role in ligand binding affinity. The docking studies of the Guggultetrol with target protein showed that this is a suitable molecule which docks well with target related to diabetes mellitus. This compound has shown promising biological activity in preliminary studies by targeting multiple signaling pathways. Thus on the basis of our in silico studies we hypothesize that this compound into guggultetrol can be inhibitory effect on against diabetes. We concluded that the natural products with interesting biological properties and structural diversity have often served as valuable lead drug candidates for the treatment of human diseases.

Keyword:     Diabetes mellitus Nymphaea pubescens


Kiran Kumar Angadi, Ravi Kumar Gundampati, Medicherla V. Jagannadham, Ammani Kandru., Molecular docking studies of guggultetrol from Nymphaea pubescens with target glucokinase (GK) related to type-II Diabetes. J App Pharm Sci. 2013; 3 (02): 127-131.

Copyright:The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text


Article Metrics
494 Views 53 Downloads 547 Total



Related Search

By author names